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Editorial
Adenovirus-Based Vectors:
Maximizing Opportunities and Optimizing a Rich
Diversity of Vectors for Gene-Based Therapy
Andrew H. Baker
This special focus issue of Human Gene Therapy ad-dresses many key aspects of adenovirus-based vectors
and their utility for gene therapy and vaccine development,
including detailed reviews and articles on adenovirus inter-
actions with the host immune system, the complications of
these effects, and how adenovirus can be developed and en-
gineered to manipulate host immune responses. One review
addresses the many challenges of manufacturing adeno-
viruses for clinical use, using adenovirus-based vaccines as
the target disease area. Collectively, the reviews offer the
latest insights into adenovirus biology, vectorology, and the
intricate interactions of this virus with the host immune
system. This issue also includes several original research
articles on adenovirus, including articles on adenovirus-
based vaccine development as well as basic adenovirus:host
interactions and vector-based retargeting.
Adenoviridae is a large family of double-stranded DNA
viruses with hosts including human and non-human primates,
rodents, amphibians, reptiles, fish, and birds (for complete
information on taxonomy and available sequences see the
very useful website edited by Dr. Balazs Harrach, Institute
for Veterinary Medical Research, Hungary, at www.vmri
.hu/*harrach/AdVtaxlong.htm). In humans, the mastade-
noviruses are pathogens that, in general, lead to self-limiting
infections in immunocompetent hosts; however, they can be
fatal in certain opportunistic situations, such as in children
undergoing bone marrow transplantation and other immune-
suppressed scenarios.
Adenovirus is a major virus-based vector system applied
to human gene therapy and used in many past and present
gene therapy trials worldwide (www.abedia.com/wiley/).
Indeed, Dr. Ron Crystal has recently been presented with
Human Gene Therapy’s pioneer award for his efforts on
early translation of adenovirus vectors into clinical gene
therapeutics (Crystal, 2014). The vast majority of early
studies used recombinant human serotype 5–based vectors
(HAdV-5) because of the existing knowledge of its tropism
in vivo as a viral vector and the creation of efficient vector
systems for production of recombinant vectors, such as the
vectors generated by Frank Graham in the 1980s. Many of
these studies progressed to clinical trials, for example, in
cardiovascular disease and cancer. HAdV5-based vectors
offer high utility because of their versatile tropism, their
large transgene carriage capacity, and its ability to achieve
efficient transgene expression independent of cell cycle and
without risk of insertional mutagenesis. The physical prop-
erties of adenovirus particles also highlight their suitability
as potentially commercial products, being relatively hardy,
non-enveloped*110 nm monodisperse particles suitable for
cGMP manufacturing.
Adenovirus vectors, mainly based on HAdV-5, have al-
ready been administered to several thousand patients with
different diseases worldwide and, despite one well-publicized
fatality involving a patient with compromised liver function
who was administered a very large dose of HAdV-5 in 1999
(Raper et al., 2003), the general safety record has been
excellent. However, compared to other vector systems, such
as retroviruses, lentiviruses, and adeno-associated viruses
(AAV), the clinical efficacy data has, in general terms, been
disappointing. This may be due to several reasons, including
longevity of transgene expression using conventional ‘‘first-
generation/E1-deleted’’ vectors and the prevalence of pre-
existing immunity to HAdV-5 in the population. The dis-
connection between the efficacy in small and large animal
models and the poor performance in clinical trials may also
be impacted by fundamental differences between virus:host
interactions among species that have often stirred the at-
tention of many translationally minded adenovirus re-
searchers. Efficient ‘‘delivery’’ of the virus is a major factor
restricting progress of many important new genetic medi-
cines, particularly those that lack direct access to the target
tissue, either surgically or through ex vivo manipulation.
Moreover, limited knowledge relating to host interac-
tions that govern infectivity, biodistribution, and toxicity
of the virus has perhaps restricted the refinement of ade-
novirus as a vector for medical applications. Notably, the
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use of these adenoviruses in early clinical trial applications
has been in the absence of important knowledge relating to
properties of the virus itself that have only recently come
to light.
In recent years, many studies on adenovirus-mediated
gene therapy have improved our understanding of the fun-
damental aspects of some adenoviruses, for example, im-
proved understanding of virus structure, interactions with
host factors via tropism-determining regions on the virus,
and the virus’s interaction with the immune system. In 2010,
Glen Nemerow’s group reported the crystal structure of
HAdV-5 at 3.5A˚ resolution, providing new insights into
both assembly and structure/function relationships that
clearly impact vector design and utility. At the cell:host
interaction level, the importance of coagulation factors in
adenovirus-mediated gene transfer has unveiled a previously
unknown function of the hexon protein in in vivo vector
tropism (Kalyuzhniy et al., 2008; Waddington et al., 2008).
Subsequent to this, the group of Andrew Byrnes has ele-
gantly shown how this interaction is essential for protection
of the virus from immune attack (at least in mice) upon
intravenous injection (Xu et al., 2013). Collectively, these
pathways impact how adenoviruses can be used clinically as
vectors for therapeutics. It is essential that we continue to
improve our understanding of the function and consequence
of these interactions if we are to optimize the clinical use of
adenovirus vectors.
The improved understanding not only provides valuable
information on the virus itself, but also how it can be
tweaked for future therapeutic applications. It is very likely
that further studies will bring other important interactions to
light; hence, it is critical for additional fundamental research
into adenovirus biology and function. This is true not only
for HAdV5, where there is already a great deal known, but
also other adenoviruses that are being used (or could po-
tentially be used) for translation to human gene therapy.
While HAdV-5-based vectors were developed for the
aforementioned reasons, there are rich resources of alter-
native adenovirus-based vectors that have not been ‘‘vec-
torized’’ to date.
Use of vectors derived from alternate human or non-
human adenoviruses is attractive for several reasons. These
include alternate infectivity/tropism profiles, differential
interaction with the immune system, and vastly different
pre-existing immunity profiles (see the insightful review by
Arnberg, 2012). Classically, switching to human adeno-
viruses that bind CD46 and other cellular receptors has led
to improved targeting, particularly of cell types such as
cancer, offering improved gene delivery (Gaggar et al.,
2003). There are examples also from non-human adeno-
viruses. Recent studies have highlighted the potential for
canine adenovirus type 2 (CAdV-2) vectors for gene transfer
in the brain, principally defined by the exquisite neuronal
tropism of this vector (Salinas et al., 2010). This is poten-
tially the tip of the iceberg, and it will be interesting to see
how the field progresses, with improved information avail-
able relating to the genome sequences, properties, and po-
tential for alternate adenovirus vectors.
One of the most important areas in which a range of
human and non-human adenoviruses are being evaluated
preclinically and clinically is in vaccination. There has been
substantial activity using HAdV-26 (Barouch et al., 2012)
and chimpanzee adenovirus-based vectors (Ewer et al., 2013).
Adenoviruses remain attractive for vaccine development since
some of them prime innate and adaptive responses, and there
have been clear advantages of maximizing and optimizing the
breadth of properties within the Adenoviridae to define the
most effective vectors in vaccine regimens.
Further focus on adenovirus biology and adenovirus-
based vectors for gene therapy will take place at the 11th
International Adenovirus Meeting in San Diego in July 2014
(http://iam.scripps.edu/). Sun, sea, sand, and adenoviruses—the
perfect combination!
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